Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ COPENHAGEN A/S  >  Novo Nordisk A/S    NOVO B   DK0060534915

NOVO NORDISK A/S

(NOVO B)
  Report
Delayed Quote. Delayed NASDAQ COPENHAGEN A/S - 03/05 10:59:58 am
427.1 DKK   -1.76%
03/05DANCANN PHARMA A/Sá : appoints Malene Gottfredsen as Product Manager
AQ
03/05NOVO NORDISKá : Deutsche Bank maintains a Buy rating
MD
03/04NOVO NORDISKá : Goldman Sachs remains its Buy rating
MD
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Copenhagen A/s
03/01/2021 03/02/2021 03/03/2021 03/04/2021 03/05/2021 Date
448.55(c) 448.3(c) 438.9(c) 434.75(c) 427.1(c) Last
2 139 514 1 794 484 1 947 786 2 720 503 2 679 650 Volume
+2.42% -0.06% -2.10% -0.95% -1.76% Change
More quotes
Financials
Sales 2021 133 B 21 284 M 21 284 M
Net income 2021 44 241 M 7 090 M 7 090 M
Net cash position 2021 8 830 M 1 415 M 1 415 M
P/E ratio 2021 22,2x
Yield 2021 2,28%
Sales 2022 144 B 23 083 M 23 083 M
Net income 2022 48 303 M 7 741 M 7 741 M
Net cash position 2022 13 046 M 2 091 M 2 091 M
P/E ratio 2022 19,8x
Yield 2022 2,47%
Capitalization 986 B 158 B 158 B
EV / Sales 2021 7,36x
EV / Sales 2022 6,76x
Nbr of Employees 45 023
Free-Float 75,1%
More Financials
Company
Novo Nordisk AS specializes in the design, production and marketing of pharmaceutical products. Net sales break down by family of products as follows: - products for treating diabetes and obesity (84.3%); - hemophilia treatment products (8.4%): mainly injections of protein; - growth hormones (6%): used for treatment of growth deficiencies in children; - hormone replacement products (1.3%): used for treatment of... 
Sector
Pharmaceuticals
Calendar
03/25 | 08:00amShareholder meeting
More about the company
Notations Surperformance© of Novo Nordisk A/S
Trading Rating : Investor Rating :
More Ratings
All news about NOVO NORDISK A/S
03/05DANCANN PHARMA A/Sá : appoints Malene Gottfredsen as Product Manager
AQ
03/05NOVO NORDISKá : Deutsche Bank maintains a Buy rating
MD
03/04NOVO NORDISKá : Goldman Sachs remains its Buy rating
MD
03/02NOVO NORDISK A/Sá : Press Release
CO
03/01PRESS RELEASE : Evotec and Chinook Therapeutics enter into strategic collaborati..
DJ
02/26NOVO NORDISK A/Sá : invests DKK 500 million in expanding tablet production facil..
AQ
02/26NOVO NORDISK A/Sá : To Invest $81.5 Million To Expand Danish Production Site
MT
02/25NOVO NORDISK A/Sá : and the University of Toronto announce joint 200 DKK million..
AQ
02/23NOVO NORDISK A/Sá : Notice for the Annual General Meeting of Novo Nordisk A/S
AQ
02/22NOVO NORDISK A/Sá : Aeterna Zentaris Announces Closing of $29.7 Million Bought D..
AQ
02/22NOVO NORDISK A/Sá : – Share repurchase programme
AQ
02/18NOVO NORDISKá : UBS reaffirms its Neutral rating
MD
02/18NOVOTEK ABá : Bokslutskommuniké januari - december -2-
DJ
02/16NOVO NORDISK A/Sá : Trading in Novo Nordisk shares by board members, executives ..
AQ
02/16NOVO NORDISKá : Deutsche Bank remains its Buy rating
MD
More news
News in other languages on NOVO NORDISK A/S
03/04Aktien Europa Schluss: Überwiegend Verluste - Vorsicht wegen Zinssorgen
03/04DGAP-HVá : Covestro AG: Bekanntmachung der -6-
02/10Calme en surface, bouillonnant en dessous
02/08Börse Stuttgart-News: Euwax Trends
02/03Aktien Europa Schluss: Uneinheitlich - Erleichterungsgewinne in Mailand
More news
Analyst Recommendations on NOVO NORDISK A/S
More recommendations
Stock Trading Strategies
NOVO NORDISK A/S - 2020
A good level to buy
BUY
More Stock Trading Analysis
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 28
Average target price 466,85 DKK
Last Close Price 427,10 DKK
Spread / Highest target 28,8%
Spread / Average Target 9,31%
Spread / Lowest Target -22,7%
EPS Revisions
Managers and Directors
NameTitle
Lars Fruergaard J°rgensen President & Chief Executive Officer
Karsten Munk Knudsen Chief Financial Officer & Executive Vice President
Helge Lund Chairman
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Henrik Ehlers Wulff Executive VP & Head-Information Technology
Sector and Competitors
1st jan.Capitalization (M$)
NOVO NORDISK A/S1.90%157 942
JOHNSON & JOHNSON-0.81%410 337
ROCHE HOLDING AG-1.63%274 753
PFIZER INC.-7.09%191 873
ABBVIE INC.-0.42%188 420
ELI LILLY AND COMPANY22.55%187 971